Analgesics in Argentina

September 2023 | 23 pages | ID: A55BF5ACE83EN
Euromonitor International Ltd

Abstracts

Retail volume sales of analgesics rebounded in 2023, following a two-year period of decline. While the COVID-19 pandemic boosted demand for acetaminophen (paracetamol), which was the only analgesic recommended by the government to alleviate the symptoms of the virus, other analgesics, such as aspirin and ibuprofen, saw a contraction in volume terms. With the worst of the pandemic behind them, consumers returned to their usual systemic analgesics, mainly aspirin and ibuprofen, in 2023.

Euromonitor International's Analgesics in Argentina report offers a comprehensive guide to the size and shape of the market at a national level. It provides the latest retail sales data 2018-2022, allowing you to identify the sectors driving growth. Forecasts to 2027 illustrate how the market is set to change.

Product coverage: Systemic Analgesics, Topical Analgesics/Anaesthetic.

Data coverage: market sizes (historic and forecasts), company shares, brand shares and distribution data.

Why buy this report?

• Get a detailed picture of the Analgesics market;
• Pinpoint growth sectors and identify factors driving change;
• Understand the competitive environment, the market’s major players and leading brands;
• Use five-year forecasts to assess how the market is predicted to develop.

Euromonitor International has over 40 years' experience of publishing market research reports, business reference books and online information systems. With offices in London, Chicago, Singapore, Shanghai, Vilnius, Dubai, Cape Town, Santiago, Sydney, Tokyo and Bangalore and a network of over 800 analysts worldwide, Euromonitor International has a unique capability to develop reliable information resources to help drive informed strategic planning.

Contents

ANALGESICS IN ARGENTINA
KEY DATA FINDINGS
2023 DEVELOPMENTS
Sales of aspirin and ibuprofen rebound in aftermath of COVID-19 pandemic
Topical analgesics with cannabidiol go from strength to strength
Bayer shows signs of recovery, but its share remains below pre-pandemic levels
PROSPECTS AND OPPORTUNITIES
Further growth expected, with stronger analgesic options benefitting from return to outdoor activities
Topical analgesics have potential for expansion
Higher doses of acetaminophen, aspirin and ibuprofen will gain additional ground
CATEGORY DATA
Table 1 Sales of Analgesics by Category: Value 2018-2023
Table 2 Sales of Analgesics by Category: % Value Growth 2018-2023
Table 3 NBO Company Shares of Analgesics: % Value 2019-2023
Table 4 LBN Brand Shares of Analgesics: % Value 2020-2023
Table 5 Forecast Sales of Analgesics by Category: Value 2023-2028
Table 6 Forecast Sales of Analgesics by Category: % Value Growth 2023-2028
CONSUMER HEALTH IN ARGENTINA
EXECUTIVE SUMMARY
Consumer health in 2023: The big picture
2023 key trends
Competitive landscape
Retailing developments
What next for consumer health?
MARKET INDICATORS
Table 7 Consumer Expenditure on Health Goods and Medical Services: Value 2018-2023
Table 8 Life Expectancy at Birth 2018-2023
MARKET DATA
Table 9 Sales of Consumer Health by Category: Value 2018-2023
Table 10 Sales of Consumer Health by Category: % Value Growth 2018-2023
Table 11 NBO Company Shares of Consumer Health: % Value 2019-2023
Table 12 LBN Brand Shares of Consumer Health: % Value 2020-2023
Table 13 Distribution of Consumer Health by Format: % Value 2018-2023
Table 14 Distribution of Consumer Health by Format and Category: % Value 2023
Table 15 Forecast Sales of Consumer Health by Category: Value 2023-2028
Table 16 Forecast Sales of Consumer Health by Category: % Value Growth 2023-2028
APPENDIX
OTC registration and classification
Vitamins and dietary supplements registration and classification
Self-medication/self-care and preventive medicine
Switches
DISCLAIMER
DEFINITIONS
SOURCES
Summary 1 Research Sources